Translating FDG to Human Studies
Early molecular imaging teams translated fluorodeoxyglucose FDG into human studies to map glucose metabolism in brain and in tumors and these pioneering clinical demonstrations showed that FDG PET could reveal metabolic activity that complemented anatomic imaging and that metabolic patterns correlated with disease activity and prognosis
From Research Tool to Clinical Modality
The clinical adoption of FDG PET required radiochemistry infrastructure for tracer production standardized uptake protocols and quantitative reconstruction methods and multicenter validation established FDG PET as a key tool in oncology neurology and cardiology for staging therapy response and for differential diagnosis
Integration with CT and Quantitative Imaging
The later integration of PET with CT provided fused metabolic and anatomic information that improved lesion localization and quantification and standardized uptake metrics became central to response assessment and to multicenter trials that use imaging biomarkers to guide therapy